

Rheological Changes During the Atrial Fibrillation

M. Gotsadze¹, T. Kandashvili², N. Momtselidze³, M. Mantskava⁴

DOI: [10.52340/GBMN.2023.01.01.05](https://doi.org/10.52340/GBMN.2023.01.01.05)

ABSTRACT

BACKGROUND

According to recent estimates atrial fibrillation (AF) affects approximately 1% of the global population with the tendency to grow over the next 50 years. Despite significant advances in the diagnosis and management of AF, it remains one of the biggest challenges for modern medicine.

OBJECTIVES

To better understand of pathological processes underlying AF, we aimed to assess relations between hemodynamic and rheological properties of blood in patients with different forms of AF.

METHODS

The erythrocyte (RBC) aggregation index (EAI), erythrocyte (RBC) deformability index (EDI), and plasma viscosity (Vpl) were measured in 70 patients with AF and 20 healthy individuals using a textural analysis system (Tas-Plus, Leitz, Germany) and innovative "Georgian technique" with the unique function of a quantitative assessment of the RBC aggregation index.

RESULTS

The mean erythrocyte (RBC) aggregation index (EAI), erythrocyte (RBC) deformability index (EDI), and plasma viscosity (PV) were statistically higher in patients with paroxysmal, persistent, and permanent AF compared to the healthy controls; however, there were no significant differences between different groups of patients with AF.

CONCLUSIONS

The findings of our investigation lead us to believe that disturbances in the hemorheological system play a crucial role in the pathogenesis of AF. These suggest that RBC aggregation is an essential factor in the progression of AF and requires constant monitoring for early prevention and adequate management of the disease.

KEYWORDS

Atrial fibrillation (AF); erythrocyte (RBC) aggregation index (EAI); erythrocyte (RBC) deformability index (EDI); hemorheology; plasma viscosity (PV).

BACKGROUND

Despite all efforts, the prevalence of atrial fibrillation (AF) and associated morbidity and mortality are increasing globally yearly.^{1,2} According to the latest evidence, the worldwide incidence of AF is 1%, which is an extremely high number. Moreover, a 2.3-fold increase in incidence is expected due to increased life expectancy and reporting of previously undiagnosed cases.^{3,4}

AF is associated with high disability and premature mortality mainly because of ischemic stroke, which is account for 20-30% of all strokes.^{5,6} Despite significant advances in the detection and treatment of AF, it remains one of the biggest challenges for modern medicine and requires a multifaceted, multidisciplinary approach to patient management.

There are many hypotheses explaining the pathogenesis of AF, including structural-functional changes in the atrial myocardium that lead to electrophysiological changes, allowing arrhythmias to be detected. In addition, there is a violation of neuro-vegetative control; a re-entry mechanism; possible ionic mechanisms of arrhythmia development, and pathological automatism in the area of the pulmonary vein

trunk.⁷ All of them entirely or partially rely on focal or small-wave mechanisms but none of them take into account the role of hemodynamical and rheological factors in the development and progression of AF.⁸ Hemorheological conditions of the blood are not considered either during the initial diagnosis of the disease or preventive measures and certainly not as a target of treatment. Furthermore, it is not clear which processes occur at the microcirculation level, where the rheological properties of the blood play a crucial role in terms of flow intensity and volumetric velocity.⁹ The rheological factors also play an important role in the development of left ventricular hypertrophy, which is one of the main risk factors of AF.¹⁰

Considering that the adequacy of microcirculation is mainly determined by the rheological properties of the blood, we aimed to assess relations between hemodynamic and rheological properties of blood in AF patients, for a better understanding of pathogenesis and optimization of disease management.



METHODS

Patient population

Overall, 70 patients (42 men and 28 women) with an average age of 65±10 years admitted to the Central Republican Hospital (Tbilisi, Georgia) because of various forms of atrial fibrillation (AF) were included in the study after final approval of the study protocol by local EC and obtaining informed consents from all patients. There was no statistically significant difference between comorbidities. The cases of heart valvular disease, decompensated type 1 diabetes mellitus, and thyroid gland pathologies were excluded.

The patients were distributed among one healthy validation (control) and three development groups based on the type of AF using recommendations of AHA/ACC/HRS and ESC guidelines for atrial fibrillation:¹²

- First development group: 22 patients with a permanent form of atrial fibrillation (12 men and 10 women);
- Second development group: 18 patients with a paroxysmal form of atrial fibrillation (13 men and 5 women);
- Third development group: 10 patients with a persistent form of atrial fibrillation, (7 men and 3 women) and
- Validation (control) group of same average age 20 healthy individuals with normal ECG and no current medication history.

Measurements

Hemorheological parameters such as red blood cell (RBC) aggregation index, RBC deformability, and blood plasma viscosity were monitored in the development and validation cohorts using the textural analysis system (Tas-Plus, Leitz, Germany) and innovative "Georgian technique" with the unique function of a quantitative assessment of the RBC aggregation index.^{11,12}

The index of RBC membrane deformability was measured by the nucleopore membrane filter method, which is based on the variation of the RBC exit rate in a porous filter (the 5 µm smallest capillary lumen) under constant pressure.^{13,14}

Plasma viscosity was determined at 37.0°C in a capillary viscometer as an average of multiple plasma viscosity measurements.

Besides routine laboratory investigations and 12-lead standard ECG in all patients, 24–48-hour ECG Holter monitoring was used in some patients to identify the paroxysmal variant of atrial fibrillation. Echocardiography was performed according to the updated recommendations of the American Society of Echocardiography.¹⁵

Statistical analysis

The obtained material was statistically processed with special biostatistical programs: Origin 8.1 (Micro cat Software, Inc.), Biostatistics for Mac (Macintosh), and Microsoft Excel. The

final evaluation of the array was done with the IBM SPSS statistical program package (version19.0). Results were expressed as mean ± SD and were considered significant at p<0.05.

RESULTS


Table 1 represents mean rheological parameters in patients with different forms of AF. The mean erythrocyte (RBC) aggregation index (EAI) was statistically higher in patients with paroxysmal, persistent, and permanent AF compared to the validation (control) group (p=0.02, p=0.02, and p=0.01, respectively); however, there were no significant differences between development groups. The highest mean EAI was in the group of patients with a permanent form of AF (42.6±10.4), and the lowest mean EAI was in the group of paroxysmal AF (32.8± 8.3, p=0.02) (Fig.1).

TABLE 1. The mean rheological parameters in patients with different forms of atrial fibrillation

	EAI	EDI	Vpl
Paroxysmal AF	32.8± 9.4	2.29±0.03	1.18±0.07
Persistent AF	39.8±13.8	2.18±0.04	1.18±0.08
Permanent AF	42.6±10.4	2.781 ± 0.09	1.20±0.07
Control	25.6±1.29	2.17±0.02	1.09±0.04


Abbreviations: AF: atrial fibrillation; EAI: erythrocyte (RBC) aggregation index; EDI: erythrocyte (RBC) deformability index; Vpl: plasma viscosity.

FIGURE 1. Erythrocyte (RBC) aggregation index (EAI) in patients with different forms of atrial fibrillation




The mean erythrocyte (RBC) deformability indexes (EDIs) were statistically higher in all development groups compared to control (p=0.01, p=0.02, and p=0.01 for paroxysmal, persistent, and permanent AF patients, respectively), with highest indices in the group of patients with permanent AF (2.27±0.02) and lowest in the group of patients with persistent AF (2.20±0.05) (Fig.2). There were no significant differences between the groups of patients with AF.

FIGURE 2. Erythrocyte (RBC) deformability index (EDI) in patients with different forms of atrial fibrillation



The mean plasma viscosity (VP) indices were statistically higher in all development groups compared to healthy control ($p=0.01$, $p=0.02$, and $p=0.01$ for paroxysmal, persistent, and permanent AF patients, respectively), without significant differences between different forms of AF (Fig.3).

FIGURE 3. Plasma viscosity (Vpl) in patients with different forms of atrial fibrillation



DISCUSSION

Despite achievements in the study of the pathogenesis of atrial fibrillation (AF), and its management, the number of patients suffering from AF is increasing rather than decreasing, and AF remains one of the major risk factors for ischemic stroke.¹⁶⁻¹⁹

The growing scientific interest regarding rheological factors in the pathogenesis of cardiovascular diseases indicates their

crucial role in chronic ischemic heart disease and arterial hypertension. For example, an increase in the RBC aggregation index is suggested as a predictor of coronary artery disease.²⁰⁻³⁰

In the present study, blood rheological parameters were studied in patients with AF for the first time in Georgia using the innovative and widely acknowledged "Georgian technique" for the assessment of red blood cell (RBC) aggregability.²⁰⁻³⁰

We discovered a link between the progression of AF and negative changes in blood rheological parameters. As is well known, hemorheological and hemodynamic factors play a crucial role in the maintenance of optimal perfusion and proper function of the myocardium as well as any other tissue. In the case of AF, special attention is paid to the different structural, functional, and electrophysiological changes of the atrial myocardium, depending on the type of AF.

The findings of our investigation lead us to believe that disturbances in the hemorheological system are at the root of the pathophysiology and severity of atrial fibrillation. Increased erythrocyte aggregation leads to the gain of peripheral resistance, which in association with irregular contractility of the left ventricle (LV), aggravates LV dysfunction and thus forms favorable conditions for the maintenance of AF.

According to our findings, blood rheological changes occur at the earliest stage of AF. The aggregation ability of RBCs, the powerful determinant of rheological changes, increases following disease progression. The rheological changes expressed during paroxysmal AF deepen in the case of the persistent and permanent types of the disease. The increased RBC aggregation and plasma viscosity aggravate existing dramatic thrombogenic changes and contribute rapid progression of AF.

These findings suggest that RBC aggregation is an important factor in the progression of AF and requires constant monitoring for early prevention and adequate management of the disease. The "Georgian technique" used in the present study allowed us to obtain accurate quantitative data and seems to be ideal for the ongoing control of blood rheological parameters, elaboration of personalized therapeutic strategies, and prevention of non-fatal/fatal complications of AF.

The main limitation of our study is the small sample size, which may have influenced the results.

AUTHOR AFFILIATION

¹Department of internal medicine N3, Tbilisi State Medical University; Central Republican Hospital. Tbilisi, Georgia;

²Department of internal medicine N3, Tbilisi State Medical University (TSMU). Tbilisi, Georgia;

³Ivane Beritashvili Center of Experimental Biomedicine, Kutaisi University. Tbilisi, Georgia;

⁴Ivane Beritashvili Center of Experimental Biomedicine; European University. Tbilisi, Georgia.

ACKNOWLEDGEMENTS

We would like to thank our colleagues for all the help and support during the present study.

REFERENCES

1. Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ, Gillum RF, Kim YH, McAnulty JH Jr, Zheng ZJ, Forouzanfar MH, Naghavi M, Mensah GA, Ezzati M, Murray CJ. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. *Circulation*, 2014 Feb 25;129(8):837-47. doi: 10.1161/CIRCULATIONAHA.113.005119
2. January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons. *Circulation* 2019; 140:e125–e151. <https://doi.org/10.1161/CIR.0000000000000665>
3. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. *Eur Heart J* 2016; 37:2893. doi: 10.1093/eurheartj/ehw210.
4. Staerk L, Sherer JA, Ko D, Benjamin EJ, Helm RH. Atrial fibrillation: epidemiology, pathophysiology, and clinical outcomes. *Circ Res* 2017 Apr 28;120(9):1501-1517. doi: 10.1161/CIRCRESAHA.117.309732.
5. Maia Gotsadze, Nugzar Narsia, Nana Momtselidze, Maia Mantskava. Effect of Xarelto on hemorheological system in patients group with permanent forms of atrial fibrillation, *World Science № 11(51)Vol.2, November 2019*, https://doi.org/10.31435/rsglobal_ws/30112019/6770
6. Krijthe BP, Kunst A, Benjamin EJ, Lip GY, Franco OH, Hofman A, Witteman JC, Stricker BH, Heeringa J. Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060. *Eur Heart J* 2013 Sep;34(35):2746-51. doi: 10.1093/eurheartj/eh280.
7. Link MS, Luttmann-Gibson H, Schwartz J, et al. Acute exposure to air pollution triggers atrial fibrillation. *J Am Coll Cardiol* .2013 Aug 27; 62(9): 816–825. doi: 10.1016/j.jacc.2013.05.043.
8. O. S. H. Barrett*, S. P. J. Macdonald†, D. A. Playford‡ Near-infrared spectroscopy-based microcirculatory assessment in acute atrial fibrillation. *Anaesthesia and Intensive Care*, 2015 Volume 43, Issue 1. <https://doi.org/10.1177/0310057X1504300116>
9. Camm A.J., Kirchhof P., Lip G.Y., Schotten U., Savelieva I. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). *Europace*. - 2010 Oct; -12(10):1360-420. doi: 10.1093/europace/euq350.
10. M Gotsadze¹, N Narsia², N Momtselidze³, M Mantskava³ Monitoring of hemorheological parameters in patients with atrial fibrillation (initial data). *Georgian Med News*. 2019 May;(290):59-63. PMID: 31322516
11. Mchedlishvili G., Basic factors determining the hemorheological disorders in the microcirculation. //Clinical Hemorheology and Microcirculation, 2004. Vol. P. 179-180.
12. Mantskava M.M., Momtselidze N.G. Haemological status of the blood (ISBN 978-3-659-66111-2). Lambert academic Publishing. www.lap-publishing.com. 2014. 78 c.
13. Timothy J.McMahon, Red Blood Cell Deformability, Vasoactive Mediators, and Adhesion. REVIEW article. *Front. Physiol.*,15 November 2019. Sec. Red Blood Cell Physiology Volume.10-2019 <https://doi.org/10.3389/fphys.2019.01417>
14. Zinchuk VV. Erythrocyte deformability: physiological aspects. *Uspekhi Fiziologicheskikh Nauk*. 2001 Jul-Sep;32(3):66-78. PMID: 11565426.
15. Roberto M. Lang, Luigi P. Badano, Victor Mor-Avi, Jonathan Afilalo, Anderson Armstrong, Laura Ernande, Frank A. Flachskampf, Elyse Foster, Steven A. Goldstein, Tatiana Kuznetsova, Patrizio Lancellotti, Denisa Muraru, Michael H. Picard, Ernst R. Rietzschel, Lawrence Rudski, Kirk T. Spencer, Wendy Tsang, Jens-Uwe Voigt. Recommendations for Cardiac Chamber Quantification by Echocardiography in Adults: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *ASE American Society of Echocardiography*. January 2015. <https://www.asecho.org/guideline/recommendations-for-cardiac-chamber-quantification-by-echocardiography-in-adults-an-update-from-the-american-society-of-echocardiography-and-the-european-association-of-cardiovascular-imaging/>
16. Gerhard Hindricks, Tatjana Potpara, Nikolaos Dagres, Elena Arbelo, Jeroen J Bax, Carina Blomström-Lundqvist, Giuseppe Boriani, Manuel Castella, Gheorghe-Andrei Dan, Polychronis E Dilaveris, Laurent Fauchier, Gerasimos Filippatos, Jonathan M Kalman, Mark La Meir, Deirdre A Lane, Jean-Pierre Lebeau, Maddalena Lettino, Gregory Y H Lip, Fausto J Pinto, G Neil Thomas, Marco Valgimigli, Isabelle C Van Gelder, Bart P Van Putte, Caroline L Watkins, ESC Scientific Document Group. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC, *European Heart Journal*, Volume 42, Issue 5, 1 February 2021, Pages 373–498. <https://doi.org/10.1093/e.2018-01-05>
17. Zeid Nesheiwat; Amandeep Goyal; Mandar Jagtap. Atrial Fibrillation. Last Update: July 31, 2022. NCB, <https://www.ncbi.nlm.nih.gov/books/NBK526072/>
18. Brieger D, Amerena J, Attia JR, Bajorek B, Chan KH, Connell C, Freedman B, Ferguson C, Hall T, Haqqani HM, Hendriks J, Hespe CM, Hung J, Kalman JM, Sanders P, Worthington J, Yan T, Zwar NA. National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Australian clinical guidelines for the diagnosis and management of atrial fibrillation 2018. *Heart Lung Circ*, 2018 Oct;27(10):1209-1266. doi: 10.1016/j.hlc.2018.06.1043 .
19. Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Chang AR, Cheng S, Das SR, Delling FN, Djousse L, Elkind MSV, Ferguson JF, Fornage M, Jordan LC, Khan SS, Kissela BM, Knutson KL, Kwan TW, Lackland DT, Lewis TT, Lichtman JH, Longenecker CT, Loop MS, Lutsey PL, Martin SS, Matsushita K, Moran AE, Mussolino ME, O'Flaherty M, Pandey A, Perak AM, Rosamond WD, Roth GA, Sampson UKA, Satou GM, Schroeder EB, Shah SH, Spartano NL, Stokes A, Tirschwell DL, Tsao CW, Turakhia MP, VanWagner LB, Wilkins JT, Wong SS, Virani SS; American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. *Circulation*. 2019 Mar 5;139(10):e56-e528. doi: 10.1161/CIR.0000000000000659.
20. Mantskava M. New and Newest approaches for measurements of blood flow. *M.Nauka*, 189, p. 2019
21. Mantskava M., Momtselidze N. and Davlianidze N. Blood Cell Deformation after Blood Loss //Journal of Biological Physics and Chemistry. 2015. Vol. 15 P. 9-11.
22. Mchedlishvili G., Mantskava M., Urdulashvili T. Appraisal of functional state of the human resistance arteries. //Russian Journal of Biomechanics. 2004. V. 8, №1. P. 55-59.
23. Urdulashvili T., Momtselidze N., Mantskava M., Naria N., Mchedlishvili G., Hemorheological disorders and arteriolar resistance during ischemic heart disease. //Clinical Hemorheology and Microcirculation. 2004. V. 30. P. 3-4

24. Momtselidze N., Mantskava M., Urdulashvili T., Narsia N., Gotsadze M., Mchedlishvili T. Comprehensive assessment of blood flow in heart insufficiency «SCI-ARTICLES», №54, 2016, стр. 5-11
25. Mantskava M., Urdulashvili T., Narsia T., Mchedlishvili T., Momtselidze N. Rheological, vascular and hemodynamic parameters during heart failure in patients with coronary artery disease. JULY 04, 2016 <http://rheology.biz/ru/rheological-vascular-and-hemodynamic3>
26. M. M. Mantskava . New non-invasive method for measuring coefficient of microcirculation. April 06, 2016 <http://rheology.biz/en/non-invasive-method/#more-3789>
27. Urdulashvili T., Momtselidze N., Mantskava M., Narsia N., Mchedlishvili G. Hemorheological, microvascular and hemodynamic disorders during coronary heart disease. DECEMBER 11, 2015 <http://rheology.biz/en/microvascular/#more-1426>
28. T. Urdulashvili, N. Momtselidze, M. Mantskava, N. Narsia, G. Mchedlishvili. Hemorheological Disorders and Arteriolar Resistance During Ischemic Heart Disease NOVEMBER 20, 2015 <http://rheology.biz/en/arteriolarresistance/#more-1941>
29. G. Mchedlishvili, M. Mantskava, T. Urdulashvili. Assessment of a functional condition of resistive arteries at the person NOVEMBER 09, 2015 <http://rheology.biz/en/category/articles/page/3/>
30. Mantskava M., Pogossova N. Complex Population Survey of Non-Invasive Arterial Elasticity, Vascular Wall Rigidity, Low Resistive Arteries Tonus and Other Parameters NOVEMBER 09, 2015 <http://rheology.biz/en/category/articles/page/3/>
31. OK Baskurt, H J Meiselman Lessons from comparative hemorheology studies. 2010;45(2-4):101-8. doi: 10.3233/CH-20101287. <https://pubmed.ncbi.nlm.nih.gov/20675889/>
32. Michael A Castellini, Oguz Baskurt, Judith M Castellini, Herbert J Meiselman. Blood rheology in marine mammals 2010 Dec 2;1:146. doi:10.3389/fphys.2010.00146. eCollection2010. <https://pubmed.ncbi.nlm.nih.gov/21423386/>
33. Adam Varga, Adam Attila Matrai, Barbara Barath, Adam Deak, Laszlo Horvath, Norbert Nemeth Interspecies Diversity of Osmotic Gradient Deformability of Red Blood Cells in Human and Seven Vertebrate Animal Species 2022 Apr 15;11(8):1351. doi: 10.3390/cells11081351. <https://pubmed.ncbi.nlm.nih.gov/35456029/>
34. Mantskava M.M., Momtselidze N.G., Davlianidze L.Sh. Rheological properties of blood in loss (experimental study) //Obshchaya Reanimatologia. 2014. V.10, №5. P.27-32. <http://dx.doi.org/10.15360/1813-9779-2014-5-27-32>
35. Caimi G., Presti R. L. Techniques to evaluate erythrocyte deformability in diabetes mellitus. //Acta Diabetol. 2004. V.41, №3, P.99-103. <http://dx.doi.org/10.1007/s00592-004-0151-1>
36. Mantskava M., Momtselidze N., Pargalava N., Mchedlishvili G. Hemorheological disorders during the 1st and 2nd types of diabetes mellitus in patients with foot gangrenes. // Clin. Hemorh. and Microcirc. 2006. V.35, №1-2. P. 307-311.